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Diffuse large B-cell lymphoma (DLBCL) is the commonest haematological malignancy, 
accounting for approximately half of all aggressive B-cell lymphomas.  Around 80% of 
patients present with DLBCL not otherwise specified (NOS); which, although potentially 
curable with combination therapy (R-CHOP), comprises a biologically heterogeneous group 
that varies widely in terms of clinical characteristics and prognostic factors.  The 
classification of DLBCL NOS into germinal centre B-cell (GCB) and activated B-cell (ABC) 
using gene-expression profiling (GEP) provided a milestone in the understanding of DLBCL 
pathogenesis; cell-of-origin (COO) is now incorporated into the latest WHO classification, 
and is a requirement for entry into most contemporary clinical trials (Swerdlow et al, 2017).  
More recently, in pursuit of molecular based approaches to the differentiation of Burkitt 
lymphoma from DLBCL, further subdivisions that include µ%XUNLWW-OLNH¶RUµhigh-JUDGH¶JHQH
expression profiles have emerged (Sha et al, 2015; Dave et al, 2006; Hummel et al, 2006).  
Set within WKH8.¶VSRSXODWLRQ-based Haematological Malignancy Research Network 
(www.hmrn.org), and utilizing both established and potentially extended classifications, the 
findings reported here are from the largest real-world DLBCL GEP series assembled to date.  
Full details of +051¶V methods can be found elsewhere (Smith et al, 2015, 2018). 
Importantly, initiated in September 2004, and tracking all patients newly diagnosed with a 
haematological malignancy until death, all diagnoses across +051¶V14 hospitals 
(catchment population ~ 4 million) are made by specialist haematopathologists at a single 
integrated haematopathology laboratory ± the Haematological Malignancy Diagnostic 
Service (www.hmds.info).   
The present report includes data on 2197 SDWLHQWV\HDUVQHZO\GLDJQRVHG with de novo 
DLBCL-NOS (ICD-O3, 9680; excluding primary CNS) between 1st September 2004 and 31st 
August 2016; all of whom were treated with curative intent and were followed-up for mortality 
through UK-wide national systems until 31st March 2018.  Of these, 706 (32.1%) had suitable 
material available for GEP; which was carried out at HMDS on RNA extracted from formalin 
fixed paraffin embedded (FFPE) pre-treatment biopsies using the Illumina WG-DASL 
platform and the ³DLBCL automatic classifier´ (DAC) to classify COO (Care et al, 2013).  
The same methods (Barrans et al, 2012; Care et al, 2013) were applied in the recent 
REMoDL-B Phase III trial, ISRCTN51837425) (Davies et al, 2015).  A transcriptomic 
classifier, originally developed to identify Burkitt lymphoma-like gene expression signatures 
(Sha et al, 2015), was then employed to further subdivide cases to include a molecular high-
grade (MHG) class. 
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The demographic and clinical characteristics of the 706 patients with GEP data are 
distributed by COO group in Table I; data on the total cohort (n=2197) are presented on the 
left.  Albeit younger (median age 66.8 years versus 68.5 years, P<0.05), the presenting 
characteristics of patients in the COO study group are broadly similar to those of the cohort 
as a whole.  Furthermore, in both groups around 89% of patients were treated with R-CHOP, 
and 2-3% with CODOX-M based chemotherapies.  Survival of patients in the COO study 
group was, however, significantly better than in the cohort as a whole; the 5-year overall 
survivals (OS) being 66.8% and 61.2% (P<0.05) respectively, and relative survivals (RS), 
which take into account the underlying age-specific and sex-specific mortality in the 
population as a whole, were 76.0% versus 71.1% (P<0.05).  
The standard 3-group classifier assigned 384 (54.4%) patients to GCB,194 (27.5%) to ABC, 
and 128 (17.1%) were unclassified.  As in other series (Scott et al, 2015), patients in the 
GCB group were significantly (P<0.05) younger (median age 66.0 years), had better survival 
(5-year OS 72.9%), and were more likely to have a MYC gene rearrangement (MYC-R, 
12.1%) than those in the ABC group (median age 70.5 years, 5-year OS 53.7%, MYC-R 
5.5%); the remaining prognostic characteristics in the two groups are comparable.   
Burkitt lymphoma displays germinal centre B-cell gene expression characteristics (Swerdlow 
et al, 2017); accordingly it is perhaps not surprising that members of the MHG subgroup 
were, almost exclusively, identified as GCB by the 3-group classifier (46/50).  Separation of 
these cases widened the survival disparity between the ABC and GCB groups (Fig 1); the 5-
year OS being 76.9%, 54.4%, 41.8% and 68.3% in the GCB, ABC, MHG, and UNC groups 
respectively.  Indeed, the survival of patients in the MHG group is substantially worse than 
that of those remaining in the GCB group (P<0.001), and significantly worse than those 
classified as ABC (P<0.05); these differences holding when the hazard ratios were adjusted 
for other prognostic factors.  Consistent with their poor survival, the cancer stage of MHG 
classified patients was more likely to be III/IV (MHG 80.4% versus GCB 61.0%, P<0.05) 
(Table 1).  It is also notable that the overall survival curve of the MHG subgroup shows a 
striking similarity to that of Burkitt lymphoma (Supplementary Figure 1), with both curves 
falling steeply before flattening around 2 years after diagnosis.  
The intrinsic relationship between MYC-R and Burkitt lymphoma is reflected in the dramatic 
excess of MYC-R in the MHG subgroup.  As is evident from Table 1, in the course of 
subsequent investigations to exclude Burkitt lymphoma, a greater proportion of MHG cases 
were assessed for MYC-R; these were, in turn, significantly more likely to be positive than 
the remaining members of the GCB class (23/50 versus 17/338, P<0.001).  Additionally, 
among those with MYC-R, MHG cases were marginally more likely than those that remained 
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in the GCB group to be double or triple hit (MYC-R together with BCL2 and/or BCL6 
rearranged), 21/23 (91.3%) compared with 13/17 (76.4%) respectively, but the difference is 
not statistically significant.  Hence, while MHG encompasses many of the double or triple hit 
lymphomas in the series, it is important to note that the GEP based grouping both subdivides 
double/triple hit lymphomas, and extends the number of cases identified as biologically 
aggressive.  
In conclusion, our findings confirm the heterogeneity of DLBCL NOS; demonstrating the 
prognostic strength of GEP in the real-world setting and supporting its use in the routine 
diagnostic process.  The discrimination of a poor-risk molecular high-grade (MHG) group 
from the conventional COO classes potentially provides the foundation for the development 
of future trials aimed at improving outcome for these patients.   
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Table I De novo diffuse large B-cell cell lymphoma (DLBCL) NOS (ICD-O3 9680/3) distributed by patient and tumour characteristics; patients treated with curative intent, 
Haematological Malignancy Research Network (HMRN) diagnoses 2004-2015  
   
Source  
Cohort 
  Study Cohort: molecular subtypes 
    Total 
Patients 
 Classic 3-group cell-of-origin (COO) stratification   Refined 4-group cell-of-origin (COO) stratification   
     GCB ABC Unclassified  GCB ABC MHG Unclassified 
Number of patients  2197  706  384 194 128  338 190 50 128 
Gender              
 Males (%) 1181 (53.8)  365 (54.2)  194 (52.6) 102 (55.4) 69 (57.0)  175 (51.8) 107 (56.3) 30 (60.0) 72 (56.2) 
Age (years)              
 Median (range) 68.5 (18.9-97.7)  66.8 (20.0-89.9)  66.0 (20.0-89.5) 70.5 (30.9-89.0) 66.0 (25.8-89.9)  66.0 (20.0-89.5) 70.0 (30.9-89.0) 67.0 (34.8-84.9) 66.0 (25.8-89.9) 
 ш ? ? ?й ? 1604 (73.0)  486 (68.8)  254 (66.1) 146 (75.3) 86 (67.2)  223 (66.0) 142 (74.7) 35 (70.0) 86 (67.2) 
Stage (%)              
 I/II 804 (40.5)  242 (36.7)  131 (36.8) 74 (39.8) 37 (31.4)  122 (39.0) 74 (40.4) 9 (19.6) 37 (31.4) 
 III/IV 1179 (59.5)  418 (63.3)  225 (63.2) 112 (60.2) 81 (68.6)  191 (61.0) 109 (59.6) 37 (80.4) 81 (68.6) 
 Not fully staged 214  46  28 8 10  25 7 4 10 
ECOG (%)              
 0/1 1679 (77.3)  550 (79.1)  295 (78.2) 155 (80.3) 100 (80.0)  263 (79.5) 152 (80.4) 35 (70.0) 100 (80.0) 
 ш ? 493 (22.7)  145 (20.9)  82 (21.8) 38 (19.7) 25 (20.0)  68 (20.5) 37 (19.6) 15 (30.0) 25 (20.0) 
 Missing 25  11  7 1 3  7 1 0 3 
IPI (%)              
 Low (0/1) 475 (28.2)  151 (26.8)  80 (26.3) 37 (23.9) 34 (32.7)  77 (28.7) 37 (24.0) 3 (8.1) 34 (32.7) 
 Intermediate (2-3) 838 (49.9)  305 (54.2)  170 (55.9) 84 (54.2) 51 (49.0)  150 (56.0) 84 (54.6) 20 (54.1) 51 (49.0) 
 High (4-5) 369 (21.9)  107 (19.0)  54 (17.8) 34 (21.9) 19 (18.3)  41 (15.3) 33 (21.4) 14 (37.8) 19 (18.3) 
 Not calculable 515  143  80 39 24  70 36 13 24 
MYC + BCL2 and/or BCL6 
rearrangement (%) 
 
 
  
 
        
  MYC-R negative  1351 (88.8)  487 (90.0)  269 (87.9) 138 (94.5) 80 (89.9)  247 (93.6) 137 (96.5) 23 (50.0) 80 (89.9) 
 MYC-R positive  177 (11.6)  54 (10.0)  37 (12.1) 8 (5.5) 9 (10.1)  17 (6.4) 5 (3.5) 23 (50.0) 9 (10.1) 
 - Single hit  52 (3.4)  13 (2.4)  4 (1.3) 5 (3.4) 4 (4.6)  4 (1.5) 3 (2.1) 2 (4.3) 4 (4.6) 
 - Double/triple hit  119 (7.8)  39 (7.2)  33 (10.8) 2 (1.4) 4 (4.5)  13 (4.9) 1 (0.7) 21 (45.7) 4 (4.5) 
 - BCL2 and/or BCL6 not done   6  2 (0.4)  0 (0) 1 (0.7) 1(1.1)  0 (0) 1 (0.7) 0 (0) 1 (1.1) 
 Missing 669  165  78 48 39  74 48 4 39 
Chemotherapy (%)              
 CHOP-R 1959 (89.2)  631 (89.4)  346 (90.1) 173 (89.2) 112 (87.5)  308 (91.1) 170 (89.5) 41 (82.0) 112 (87.5) 
 CODOX-M based 50 (2.2)  18 (2.5)  13 (3.4) 1 (0.5) 4 (3.1)  10 (3.0) 1 (0.5) 3 (6.0) 4 (3.1) 
5-year survival (%)              
 Overall (OS) 61.2  66.8  72.9 53.7 68.3  76.9 54.4 41.8 68.3 
Relative (RS)  71.1  76.0  81.7 62.2 77.8  86.1 62.9 44.4 77.8 
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Figure Legend 
x Figure 1: De novo diffuse large B-cell cell lymphoma (DLBCL) NOS overall survival stratified 
by cell of origin (median age at diagnosis);  patients treated with curative intent, 
Haematological Malignancy Research Network (HMRN) diagnoses 2004-2015  
 
x Supplementary Figure: De novo molecular high grade (MHG) diffuse large B-cell cell 
lymphoma NOS and Burkitt lymphoma overall survival curves (median age at diagnosis); 
patients treated with curative intent, Haematological Malignancy Research Network (HMRN) 
diagnoses 2004-2015  
 
